-
A Foundational Study On Stroke Is Ready. Here Is Why It's Important
Monday, September 12, 2022 - 2:26pm | 763Read More...Biopharma company Algernon Pharmaceuticals Inc's (OTC: AGNPF) recently announced plan for a Phase 1 clinical study on DMT for human stroke has just received approval from the Stichting Beoordeling Ethiek Biomedisch Onderzoek (BEBO), an independent Medical Research Ethics Committee....
-
Algernon Pharmaceuticals Closes Private Placement Round, Announces New Shareholder Distribution
Tuesday, August 23, 2022 - 5:13pm | 557Read More...Biotech clinical-stage company Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has closed its previously announced non-brokered private placement for a total of 373,900 of its units at $3.75 per share, for gross proceeds of $1,402,125. Algernon focuses on investigating new disease applications...
-
Psyched: Boston Suburbs Decriminalize Psilocybin, Delic Begins Psychedelic Treatments, Australia Denies Legalization
Saturday, February 6, 2021 - 9:37am | 1449Read More...Boston Suburbs Look To Decriminalize Natural Psychedelics Two Boston suburbs are the latest U.S. jurisdictions to eliminate penalties on the possession and cultivation of entheogenic plants and fungi. That includes psilocybin mushrooms, ayahuasca, the peyote cacti and the iboga...
